logo-loader

Evgen Pharma ready to prove broccoli drug's worth

Published: 16:33 06 Jul 2016 BST

Can a humble molecule with a heritage in broccoli really cure any number of ailments?
That’s the premise behind Evgen Pharma (LON:EVG) and chief executive Stephen Franklin says that after eight years of development work, the company has arrived at the business end of proving it.
A phase II trial for the molecule, sulforaphane, as a treatment for a rare form of stroke has just got underway, while the company also has the funds for a breast cancer trial.
Results due in 2018 and Franklin says all investors have to do until then is hold their nerve.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 7 minutes ago